JP4776845B2 - ヒトナチュラルキラー細胞によって媒介される天然細胞毒性に関連した新規トリガリングレセプターおよび同一の性質を有する抗体 - Google Patents
ヒトナチュラルキラー細胞によって媒介される天然細胞毒性に関連した新規トリガリングレセプターおよび同一の性質を有する抗体 Download PDFInfo
- Publication number
- JP4776845B2 JP4776845B2 JP2001538509A JP2001538509A JP4776845B2 JP 4776845 B2 JP4776845 B2 JP 4776845B2 JP 2001538509 A JP2001538509 A JP 2001538509A JP 2001538509 A JP2001538509 A JP 2001538509A JP 4776845 B2 JP4776845 B2 JP 4776845B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- nkp30
- seq
- isolated antibody
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000003013 cytotoxicity Effects 0.000 title claims abstract description 70
- 231100000135 cytotoxicity Toxicity 0.000 title claims abstract description 70
- 210000000822 natural killer cell Anatomy 0.000 title claims description 201
- 230000001404 mediated effect Effects 0.000 title description 34
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims abstract description 164
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims abstract description 156
- 210000004027 cell Anatomy 0.000 claims description 161
- 238000000034 method Methods 0.000 claims description 84
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 210000004408 hybridoma Anatomy 0.000 claims description 31
- 239000012472 biological sample Substances 0.000 claims description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 26
- 229920001184 polypeptide Polymers 0.000 claims description 25
- 230000000638 stimulation Effects 0.000 claims description 20
- 238000000746 purification Methods 0.000 claims description 19
- 238000009739 binding Methods 0.000 claims description 16
- 238000004132 cross linking Methods 0.000 claims description 14
- 102000002752 Natural Cytotoxicity Triggering Receptor 3 Human genes 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 230000004936 stimulating effect Effects 0.000 claims description 10
- 238000002054 transplantation Methods 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 230000004962 physiological condition Effects 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 7
- 230000001976 improved effect Effects 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims 3
- 231100000419 toxicity Toxicity 0.000 claims 3
- 102000005962 receptors Human genes 0.000 abstract description 62
- 150000001875 compounds Chemical class 0.000 abstract description 58
- 210000001939 mature NK cell Anatomy 0.000 abstract description 4
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 70
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 65
- 108020003175 receptors Proteins 0.000 description 61
- 239000012634 fragment Substances 0.000 description 37
- 239000002299 complementary DNA Substances 0.000 description 31
- 230000001461 cytolytic effect Effects 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 28
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 27
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 27
- 239000000047 product Substances 0.000 description 26
- 210000004881 tumor cell Anatomy 0.000 description 26
- 108091033319 polynucleotide Proteins 0.000 description 23
- 102000040430 polynucleotide Human genes 0.000 description 23
- 239000002157 polynucleotide Substances 0.000 description 23
- 230000000873 masking effect Effects 0.000 description 20
- 101000589307 Homo sapiens Natural cytotoxicity triggering receptor 3 Proteins 0.000 description 19
- 239000000427 antigen Substances 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 18
- 230000002163 immunogen Effects 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 239000000523 sample Substances 0.000 description 17
- 201000001441 melanoma Diseases 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 230000009089 cytolysis Effects 0.000 description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 14
- 230000006037 cell lysis Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 239000003446 ligand Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 230000009257 reactivity Effects 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 12
- 102000018358 immunoglobulin Human genes 0.000 description 12
- 230000006698 induction Effects 0.000 description 12
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 11
- 230000006051 NK cell activation Effects 0.000 description 11
- 238000000636 Northern blotting Methods 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 11
- 239000011575 calcium Substances 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 230000002147 killing effect Effects 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
- 241000283707 Capra Species 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 238000010369 molecular cloning Methods 0.000 description 9
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 9
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 8
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 8
- 230000000735 allogeneic effect Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 239000011886 peripheral blood Substances 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000010240 RT-PCR analysis Methods 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 102000052554 human NCR3 Human genes 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 102000043129 MHC class I family Human genes 0.000 description 5
- 108091054437 MHC class I family Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 102000002755 Natural Cytotoxicity Triggering Receptor 1 Human genes 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 108091008042 inhibitory receptors Proteins 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000009738 saturating Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
- 108010004220 Natural Cytotoxicity Triggering Receptor 2 Proteins 0.000 description 4
- 102000002751 Natural Cytotoxicity Triggering Receptor 2 Human genes 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000020411 cell activation Effects 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 101100351529 Arabidopsis thaliana MRN1 gene Proteins 0.000 description 3
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 102000003812 Interleukin-15 Human genes 0.000 description 3
- 108090000172 Interleukin-15 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000002698 KIR Receptors Human genes 0.000 description 3
- 108010043610 KIR Receptors Proteins 0.000 description 3
- 101710195102 Lymphocyte cytosolic protein 2 Proteins 0.000 description 3
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 3
- 101100365690 Mus musculus Shc1 gene Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 102000004422 Phospholipase C gamma Human genes 0.000 description 3
- 108010056751 Phospholipase C gamma Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000005220 cytoplasmic tail Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 101150098203 grb2 gene Proteins 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000010185 immunofluorescence analysis Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 101150012554 shc gene Proteins 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 2
- 108010077854 Natural Killer Cell Receptors Proteins 0.000 description 2
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 229920004929 Triton X-114 Polymers 0.000 description 2
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011266 cytolytic assay Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000012921 fluorescence analysis Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 230000016178 immune complex formation Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 108020004463 18S ribosomal RNA Chemical group 0.000 description 1
- 108020005096 28S Ribosomal RNA Proteins 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 241000744472 Cinna Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100038385 Coiled-coil domain-containing protein R3HCC1L Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150067056 Epsilon gene Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
- 101000743767 Homo sapiens Coiled-coil domain-containing protein R3HCC1L Proteins 0.000 description 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 1
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 description 1
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 description 1
- 101001065559 Homo sapiens Lymphocyte antigen 6D Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 101150069255 KLRC1 gene Proteins 0.000 description 1
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 101100341510 Mus musculus Itgal gene Proteins 0.000 description 1
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 1
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 208000037432 Thymic tumor Diseases 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HEAFLBOWLRRIHV-UHFFFAOYSA-N [Na].[P] Chemical compound [Na].[P] HEAFLBOWLRRIHV-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000056088 human LY6D Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- -1 injectable solution Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000503 lectinlike effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44051499A | 1999-11-15 | 1999-11-15 | |
| CA2,288,307 | 1999-11-15 | ||
| CA2288307A CA2288307C (en) | 1999-11-15 | 1999-11-15 | Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same |
| US09/440,514 | 1999-11-15 | ||
| PCT/EP2000/011697 WO2001036630A2 (en) | 1999-11-15 | 2000-11-15 | Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003523735A JP2003523735A (ja) | 2003-08-12 |
| JP2003523735A5 JP2003523735A5 (enExample) | 2008-01-17 |
| JP4776845B2 true JP4776845B2 (ja) | 2011-09-21 |
Family
ID=25681295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001538509A Expired - Fee Related JP4776845B2 (ja) | 1999-11-15 | 2000-11-15 | ヒトナチュラルキラー細胞によって媒介される天然細胞毒性に関連した新規トリガリングレセプターおよび同一の性質を有する抗体 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1240326B1 (enExample) |
| JP (1) | JP4776845B2 (enExample) |
| AT (1) | ATE423848T1 (enExample) |
| AU (1) | AU783899B2 (enExample) |
| DE (1) | DE60041655D1 (enExample) |
| DK (1) | DK1240326T3 (enExample) |
| ES (1) | ES2321687T3 (enExample) |
| WO (1) | WO2001036630A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10261223A1 (de) * | 2002-12-20 | 2004-07-08 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen |
| WO2004056392A1 (en) * | 2002-12-23 | 2004-07-08 | Innate Pharma | Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same |
| EP1445614A1 (en) * | 2003-02-06 | 2004-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | A method for the in vitro assessment of the progression status of an HIV virus in an invidual |
| CA2532547C (en) | 2003-07-24 | 2020-02-25 | Innate Pharma | Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds |
| EP1740618A1 (en) * | 2004-04-30 | 2007-01-10 | Innate Pharma | Compositions and methods for enhancing nk cell activity |
| RU2395294C2 (ru) * | 2004-06-18 | 2010-07-27 | Дженентек, Инк. | Способы применения агонистов аро-2l-рецепторов и активаторов nk-клеток |
| EP1773884B1 (en) | 2004-08-03 | 2012-03-07 | Innate Pharma | Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor |
| EP1626059A1 (en) * | 2004-08-09 | 2006-02-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2 |
| PT1831258E (pt) | 2004-12-28 | 2016-01-07 | Univ Genova | Anticorpos monoclonais contra nkg2a |
| EP2322557B1 (en) | 2005-10-14 | 2017-08-30 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| ES2629440T5 (es) * | 2007-10-04 | 2020-11-20 | Zymogenetics Inc | zB7H6 miembro de la familia B7 y composiciones y métodos relacionados |
| CA2990520C (en) * | 2015-07-24 | 2023-06-27 | Innate Pharma | Methods for detecting tissue infiltrating nk cells |
| CA3079363A1 (en) | 2017-11-21 | 2019-05-31 | Innate Pharma | Multispecific antigen binding proteins |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| WO2020172605A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| CA3166629A1 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2023110937A1 (en) | 2021-12-14 | 2023-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
| JP2023109240A (ja) * | 2022-01-27 | 2023-08-08 | 学校法人 東洋大学 | ナチュラルキラー細胞活性の測定方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999023867A2 (en) * | 1997-11-07 | 1999-05-20 | Biogen, Inc. | Bmog, a protein member of the myelin-oligodendrocyte glycoprotein family and its use |
| WO1999049881A2 (de) * | 1998-03-27 | 1999-10-07 | Gabriele Multhoff | Verwendung von hsp70 protein |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69430846T2 (de) * | 1993-08-27 | 2003-01-16 | Dana-Farber Cancer Institute, Boston | Für natürliche killerzellen spezifische antigene und sie identifizierende antikörper |
-
2000
- 2000-11-15 WO PCT/EP2000/011697 patent/WO2001036630A2/en not_active Ceased
- 2000-11-15 ES ES00989877T patent/ES2321687T3/es not_active Expired - Lifetime
- 2000-11-15 DK DK00989877T patent/DK1240326T3/da active
- 2000-11-15 JP JP2001538509A patent/JP4776845B2/ja not_active Expired - Fee Related
- 2000-11-15 AU AU26677/01A patent/AU783899B2/en not_active Ceased
- 2000-11-15 AT AT00989877T patent/ATE423848T1/de active
- 2000-11-15 DE DE60041655T patent/DE60041655D1/de not_active Expired - Lifetime
- 2000-11-15 EP EP00989877A patent/EP1240326B1/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999023867A2 (en) * | 1997-11-07 | 1999-05-20 | Biogen, Inc. | Bmog, a protein member of the myelin-oligodendrocyte glycoprotein family and its use |
| WO1999049881A2 (de) * | 1998-03-27 | 1999-10-07 | Gabriele Multhoff | Verwendung von hsp70 protein |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1240326A2 (en) | 2002-09-18 |
| ATE423848T1 (de) | 2009-03-15 |
| DK1240326T3 (da) | 2009-06-02 |
| WO2001036630A2 (en) | 2001-05-25 |
| EP1240326B1 (en) | 2009-02-25 |
| AU783899B2 (en) | 2005-12-22 |
| ES2321687T3 (es) | 2009-06-10 |
| JP2003523735A (ja) | 2003-08-12 |
| WO2001036630A9 (en) | 2002-09-19 |
| AU2667701A (en) | 2001-05-30 |
| DE60041655D1 (de) | 2009-04-09 |
| WO2001036630A3 (en) | 2001-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100015153A1 (en) | Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the Same | |
| JP4776845B2 (ja) | ヒトナチュラルキラー細胞によって媒介される天然細胞毒性に関連した新規トリガリングレセプターおよび同一の性質を有する抗体 | |
| JP3703834B2 (ja) | 活性化ｃｄ４▲上＋▼ｔ細胞の表層上のレセプターに対するリガンド（ａｃｔ−４−ｌ） | |
| AU685745B2 (en) | Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily | |
| WO1994027638A1 (en) | Monoclonal antibodies that block ligand binding to the cd22 receptor in mature b cells | |
| US5710262A (en) | Nucleic acid encoding HB15 polypeptides | |
| AU716731B2 (en) | Monoclonal antibody reacting specifically with Fas ligand and process for producing the same | |
| WO1995029236A9 (en) | Lymphocyte activation antigens and antibodies thereto | |
| US7138243B2 (en) | NTB-A, a surface molecule involved in natural killer cells activity | |
| AU2002325333A1 (en) | NTB-A, a surface molecule involved in natural killer cells activity | |
| US20080248045A1 (en) | Polypeptides having a triggering nk activity and biological applications | |
| CA2112468A1 (en) | Dnas encoding proteins active in lymphocyte-mediated cytotoxicity | |
| CA2288307C (en) | Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same | |
| US5646251A (en) | Alloreaction-associated antigen (ARAG): a novel member of the immunoglobulin gene superfamily |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050331 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071115 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071115 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080522 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20081009 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100630 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100924 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110105 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110506 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110601 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110629 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140708 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |